disopyramide has been researched along with Long QT Syndrome in 15 studies
Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study suggests that the patients showing bradycardia dependent QT prolongation are also more markedly affected by disopyramide and that abnormal potassium channel may be the underlying mechanism." | 7.70 | Relation between bradycardia dependent long QT syndrome and QT prolongation by disopyramide in humans. ( Abe, A; Aizawa, Y; Chinushi, M; Furushima, H; Niwano, S; Ohhira, K, 1998) |
| "This study suggests that the patients showing bradycardia dependent QT prolongation are also more markedly affected by disopyramide and that abnormal potassium channel may be the underlying mechanism." | 3.70 | Relation between bradycardia dependent long QT syndrome and QT prolongation by disopyramide in humans. ( Abe, A; Aizawa, Y; Chinushi, M; Furushima, H; Niwano, S; Ohhira, K, 1998) |
| "disopyramide was administered intra-vascularly in separate experiments, and the doses were predicted only from the pharmacological data." | 1.31 | Bioavailability assessment of disopyramide using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat. ( Iwanaga, K; Kakemi, M; Maekawa, C; Miyazaki, M; Morimoto, K, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 6 (40.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirose, K | 1 |
| Yamaguchi, H | 1 |
| Oshima, Y | 1 |
| Choraku, M | 1 |
| Hirono, A | 1 |
| Takamori, N | 1 |
| Tamura, K | 2 |
| Matsuhashi, T | 1 |
| Sato, T | 1 |
| Aizawa, Y | 2 |
| Takatsuki, S | 1 |
| Asajima, H | 1 |
| Saito, N | 1 |
| Ohmura, Y | 1 |
| Ohmura, K | 1 |
| Yoshida, H | 1 |
| Sugiyama, A | 1 |
| Satoh, Y | 1 |
| Ishida, Y | 1 |
| Kugiyama, K | 1 |
| Hashimoto, K | 1 |
| Ridley, JM | 1 |
| Milnes, JT | 1 |
| Benest, AV | 1 |
| Masters, JD | 1 |
| Witchel, HJ | 1 |
| Hancox, JC | 1 |
| Hanada, E | 1 |
| Ohtani, H | 1 |
| Hirota, M | 1 |
| Uemura, N | 1 |
| Nakaya, H | 1 |
| Kotaki, H | 1 |
| Sato, H | 1 |
| Yamada, Y | 1 |
| Iga, T | 1 |
| Dumaine, R | 1 |
| Antzelevitch, C | 1 |
| Kurita, T | 1 |
| Ohe, T | 1 |
| Shimizu, W | 1 |
| Suyama, K | 1 |
| Aihara, N | 1 |
| Takaki, H | 1 |
| Kamakura, S | 1 |
| Shimomura, K | 1 |
| Panhuyzen-Goedkoop, NM | 1 |
| Crijns, HJ | 1 |
| Wolff, GS | 1 |
| Furushima, H | 1 |
| Niwano, S | 1 |
| Chinushi, M | 1 |
| Ohhira, K | 1 |
| Abe, A | 1 |
| Matsunaga, T | 1 |
| Mitsui, T | 1 |
| Harada, T | 1 |
| Inokuma, M | 1 |
| Murano, H | 1 |
| Shibutani, Y | 1 |
| Miyazaki, M | 1 |
| Maekawa, C | 1 |
| Iwanaga, K | 1 |
| Morimoto, K | 1 |
| Kakemi, M | 1 |
| Kasanuki, H | 1 |
| Ohnishi, S | 1 |
| Nirei, T | 1 |
| Shoda, M | 1 |
| Hosoda, S | 1 |
| Gardner, MJ | 1 |
| McCarthy, DM | 1 |
| Josephson, ME | 1 |
1 review available for disopyramide and Long QT Syndrome
| Article | Year |
|---|---|
Unexplained syncope: clinical management.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Behavior Ther | 1997 |
14 other studies available for disopyramide and Long QT Syndrome
| Article | Year |
|---|---|
Severe respiratory failure and torsades de pointes induced by disopyramide in a patient with myasthenia gravis.
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Cholinergic Antagonists; Disopyramide; Electrocardiogra | 2008 |
Recurrent Torsade de Pointes during mild hypothermia therapy for a survivor of sudden cardiac arrest due to drug-induced long-QT syndrome.
Topics: Aged; Anti-Arrhythmia Agents; Disopyramide; Female; Heart Arrest; Humans; Hypothermia, Induced; Long | 2010 |
Lansoprazole precipitated QT prolongation and torsade de pointes associated with disopyramide.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Arrhythmia Agents; Anti-Ulcer Agents; Disopyrami | 2012 |
Effects of disopyramide and mexiletine on the terminal repolarization process of the in situ heart assessed using the halothane-anesthetized in vivo canine model.
Topics: Action Potentials; Anesthetics, Inhalation; Animals; Anti-Arrhythmia Agents; Blood Pressure; Cardiac | 2002 |
Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cell Line; Cell Membrane; Disopyramide; DNA-Bindi | 2003 |
Inhibitory effect of erythromycin on potassium currents in rat ventricular myocytes in comparison with disopyramide.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Delayed Rectifier Potassi | 2003 |
Disopyramide: although potentially life-threatening in the setting of long QT, could it be life-saving in short QT syndrome?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardiac; Disopyramide; Drug Interaction | 2006 |
Early afterdepolarizationlike activity in patients with class IA induced long QT syndrome and torsades de pointes.
Topics: Action Potentials; Aged; Anti-Arrhythmia Agents; Disopyramide; Electrocardiography; Electrophysiolog | 1997 |
[Iatrogenic collapse; can this be prevented?].
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Disopyramide; Erythro | 1997 |
Relation between bradycardia dependent long QT syndrome and QT prolongation by disopyramide in humans.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Bradycardia; Cardiac Pacing, Artificial; Dis | 1998 |
QT corrected for heart rate and relation between QT and RR intervals in beagle dogs.
Topics: Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Disopyramide; Dogs; Electrocardiography, Am | 1997 |
Bioavailability assessment of disopyramide using pharmacokinetic-pharmacodynamic (PK-PD) modeling in the rat.
Topics: Algorithms; Animals; Anti-Arrhythmia Agents; Antifungal Agents; Area Under Curve; Biological Availab | 2000 |
Acquired long QT syndrome due to antiarrhythmic drugs and bradyarrhythmias.
Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Bradycardia; Disopyramide; Electrocardiograp | 1992 |
Effect of myocardial ischemia and type I antiarrhythmic drug therapy on exercise QT intervals.
Topics: Anti-Arrhythmia Agents; Coronary Disease; Disopyramide; Electrocardiography; Exercise Test; Heart Co | 1985 |